⌕
NewAmsterdam Pharma · NAMS · Nasdaq
Tenet 58 · Mixed
Compare
$19.46−3.38%At closeTenet 58 · Mixed
$19.46−0.68 (−3.38%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

NewAmsterdam Pharma (NAMS) Institutional Ownership

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice

5 figures withheld by our checks. Each blank figure names its reason.

13F fund flowQuarter ended Jun 30, 2026. Withheld: many filers have already reported a later quarter, so their changes in this quarter are not on file and the counts of new, added, trimmed and closed positions are not shown. These positions are 140 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
SHARES HELD BY 13F FILERS
withheld
withheld by our checks · 197 filers, Jun 30, 2026
# 13F FUNDS
197
13F VALUE
$4.2B
124.4M shares
Withheld: the 13F filers report more shares than the company has outstanding, which happens when shared or lent shares are counted twice. The filer count, shares and value are as filed.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Sep 30, 2026Kastelein Johannes Jacob PieterChief Scientific OfficerAcquired · Option exercise50,246—↗
Sep 30, 2026Kastelein Johannes Jacob PieterChief Scientific OfficerDisposed · Open-market sale50,246$25.03↗
Sep 30, 2026Kastelein Johannes Jacob PieterChief Scientific OfficerDisposed · Option exercise50,246Option (right to buy)—↗
Sep 14, 2026Davidson Michael H.Chief Executive OfficerAcquired · Open-market buy10,000$22.65↗
Sep 4, 2026Smither John WdirectorDisposed · Open-market sale1,600$25.32↗
Sep 1, 2026Gunning Robert WilliamVice President, ControllerAcquired · Grant / award3,200—↗
Sep 1, 2026Gunning Robert WilliamVice President, ControllerAcquired · Grant / award14,000Option (right to buy)—↗
Aug 24, 2026Kastelein Johannes Jacob PieterChief Scientific OfficerAcquired · Option exercise125,000—↗
Aug 24, 2026Kastelein Johannes Jacob PieterChief Scientific OfficerDisposed · Open-market sale125,000$26.91↗
Aug 24, 2026Kastelein Johannes Jacob PieterChief Scientific OfficerDisposed · Option exercise125,000Option (right to buy)—↗
Jul 20, 2026Kooij Louise FrederikaChief Accounting OfficerAcquired · Option exercise25,000$11.90↗
Jul 20, 2026Kooij Louise FrederikaChief Accounting OfficerAcquired · Option exercise80,000$11.17↗
Jul 20, 2026Kooij Louise FrederikaChief Accounting OfficerDisposed · Open-market sale70,200$29.96↗
Jul 20, 2026Kooij Louise FrederikaChief Accounting OfficerDisposed · Open-market sale31,885$31.05↗
Jul 20, 2026Kooij Louise FrederikaChief Accounting OfficerDisposed · Open-market sale2,915$31.71↗
Jul 20, 2026Kooij Louise FrederikaChief Accounting OfficerDisposed · Option exercise25,000Option (right to buy)—↗
Jul 20, 2026Kooij Louise FrederikaChief Accounting OfficerDisposed · Option exercise80,000Option (right to buy)—↗
Jun 22, 2026Kooij Louise FrederikaChief Accounting OfficerAcquired · Option exercise25,000$10.90↗
Jun 22, 2026Kooij Louise FrederikaChief Accounting OfficerAcquired · Option exercise15,000$11.90↗
Jun 22, 2026Kooij Louise FrederikaChief Accounting OfficerDisposed · Open-market sale39,700$30.20↗

* Holdings as reported for Jun 30, 2026, 140 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How many 13F filers hold NewAmsterdam Pharma?

NewAmsterdam Pharma was held by 197 13F filers as of Jun 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.